Member Info for Size82

Still, a jv might be better than a full rights issue and even a further step down the road going bust! Fortunately we have no debt. Long may it continue!

Who knows for sure, but you'd expect dilution to be pretty darn from brutal, especially if only one suiter is involved and the cash balance is running down.

Sure Mani, it is a given and I don't want to share!

As Doc.Daneeka points out "STRIVE is the only non-dilutory route forward".

Repeat: "STRIVE is the only non-dilutory route forward".

Anything else is a disaster for shareholders and the final nail in the coffin for The Sprinter fund raise and I dare say the CEO!

If I was RM and Co I'd be looking to get a ph4 trial for covid inpatients who really are suffering. Quickest route to commercialisation and "we know it works" lol

Good post Doc.Dan (11.55 am)

Fruits, hopefully something is brewing state side.... we wait... some more patiently than others.

In your opinion does the hie point more towards a PT (STRIVE) or JV with BP (Janssen)?

Mani,

I'd agree with your following statement which I've reposted except fot a couple of points.

1).TGF might agree to a raise as a last resort. You'd think at that point though they might just try and take the company private for peanuts, hoping PIs throw in the towel, and fund a trial themselves. Not what they normally do though according to other posters on this forum (but there is always a first time).

2). I'm not sure Synairgen would need to raise cash to keep the lights on during a PT. We'll see the status of the accounts in a few months, but I would have thought they'll have enough cash on account to last (if prudently managed).

IMO in the current situation a CEO should always exhaust platform trial options first. I would hope Synairgen have been given the tentative nod for STRIVE. However, I don't see why it wouldn't be made official and the trial protocol worked on thereafter so perhaps not. The relationship with Janssen muddies the picture.

I share fellow forum members frustrations at the lack of communication from RM & Co.

Mani's post.

"I don't see TGF agreeing to a placing. They are too close to 30% to participate,
if they wanted to make an offer they could do that now and not allow another major
investor on board to dilute their position. I can see problems with a JV if SNG
are wiling to give too much away and TGF do not agree.

STRIVE looks to suit us as long as the protocol is geared towards our strengths, but
cannot see results before end of 2024 and we would need some funds to see it through.

RM needs to pull something off sooner rather than later, time was on our side after SPRINTER
with a solid cash position, but as the months roll on without a secured solution it is an
uneasy time for shareholders".

I hope something is brewing though...

Hi Wigster, I think you are mistaken. Linkedin post on international women's day earlier and other posts last week. GLA

Agreed in the risk reward point. Not only for the 'pop' when / If a trial is announced, but also longer term if authorisation is granted on the back of successful results. The size of the return will likely depend on the avoidance of new trial funding dilution - either through a JV with BP or a raise. The latter would obviously be catastrophic!! STRIVE remains the great white hope for me.

Personally I think Synairgen's comms should be better, letting the market know they are still pursuing a PT for example. I thought the use of LinkedIn was inappropriate at New Year. Not all investors would have seen it. Arguably there was RNS level material included on trial strategy.

Hopefully patience will pay off.
Good luck all. X

Thanks for the heads up Gunto. I'll take what's posted on that board with a v large pinch of salt though.

Easiest way to know though would be for Synairgen to actually let their shareholders know they have applied to be on STRIVE and under what basis (I.e. covid, multi virus).

It's unclear to me why STRIVE wouldn't trial Synairgen just for covid. Pretty straightforward as Dok.Daneeka points out. They've had a headstart in designing a trial protocol from the Sprinter results. I'm slightly perplexed why we'd have to wait until mid year for this. Even if STRIVE are going down the multi virus trial route they need 1,000 + parents for each virus. One virus at a time.
GLA

Hi Gunto, how do you know the second agent for STRIVE won't be announced until mid year? Apologies if I missed a previous answer on this.
Many thanks
GLA

It amazes me how these conferences get hyped up. Nothing commercial is ever, ever going to be released via this type of forum.

Let's hope though it is helping to build the case for our inclusion on STRIVE. That said, the NIH should have made up there minds in about an hr having reviewed the data released at the ATS. All IMHO

I doubt an RNS, but the presentation will go on the website - probably after a few days.

Tommy, when did he state the following:

"RM has been very clear from the outset that he won’t announce until it’s signed and sealed, whether that be a trial or a JV".

Btw, not disagreeing just checking the point in time you are referring too.
Gla

Agreed Doc

* re. Great white hope. Stockpiling, not a really nasty variant emerging

Doc83, if Synairgen trial for multiple viruses and succeed then I'd say the upside has increased.

If we just trial for covid only (perhaps via STRIVe), specifically for high risk, hospitalised patients as identified in the ATS presentation / peer reviewed journal, then maybe the upside has diminished due to the size of the market on an annual basis. However, this excludes pandemic response stockpiling and / or a really nasty variant emerging . This is the great white hope for me. Just need to get that first authorisation and not f*ck up another phase 3 (if we can get on one without having out pants pulled down)!! GLA, news must surely be relitively close....

Bullish as ever Tommy